 Foscarnet therapy patients AIDS acyclovir-resistant varicella-zoster virus infection OBJECTIVE foscarnet potential efficacy treatment acyclovir-resistant mucocutaneous varicella-zoster infection patients acquired immunodeficiency syndrome AIDS DESIGN Open-label study SETTING university medical centers PATIENTS patients AIDS thymidine-kinase-deficient -altered strains varicella-zoster virus INTERVENTION Foscarnet mg/kg body hours infusions days MAIN RESULTS patients response therapy tested patients culture negative virus foscarnet therapy Results fluorescent antigen positive therapy patients patients concomitant clinical failure patient patient complete emergence resistance serial specimens foscarnet therapy CONCLUSION Foscarnet effective tolerable antiviral agent patients acyclovir-resistant varicella-zoster virus infection optimal dosage duration therapy require study relation clinical findings in-vitro susceptibility results